- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.02. | Trump orders agencies to plan for 'large-scale' job cuts | ||
| 11.02. | Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK | ||
| 11.02. | Novartis pays $925M to reel in a startup it helped launch | ||
| 11.02. | Vertex COO Arbuckle to step down later this year | ||
| 10.02. | AbbVie, Pfizer gain FDA OK for novel antibiotic | ||
| 10.02. | Axsome secures top drug's future with Teva patent settlement | ||
| 10.02. | Pliant shares collapse as company halts fibrosis drug study | ||
| 10.02. | The role of diagnostics in advancing antibody-drug conjugates | ||
| 07.02. | Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty | ||
| 07.02. | Immune drugmakers Alumis and Acelyrin to merge | ||
| 07.02. | Vertex challenger Sionna prices $191M IPO | ||
| 06.02. | Bristol Myers, bracing for key patent losses, deepens cost-cutting plan | ||
| 06.02. | Eli Lilly's earnings, shares lifted by obesity drug sales | ||
| 06.02. | Bristol Myers gives first peek at closely watched launch of schizophrenia drug | ||
| 06.02. | Pfizer taps a former Novartis exec to lead cancer drug push | ||
| 05.02. | GSK, Pfizer sales of RSV shots slow as vaccination rates ebb | ||
| 05.02. | Novo outlines new late-stage study of obesity drug CagriSema | ||
| 05.02. | Illumina placed on China's 'unreliable entity' list | ||
| 05.02. | Amgen obesity drug on hold; Regeneron sets first dividend | ||
| 04.02. | RFK Jr. secured support of key Republican with vaccine pledges | ||
| 04.02. | Flagship-backed Omega signals it's headed toward bankruptcy | ||
| 04.02. | Merck shares tumble as company pauses Gardasil shipments to China | ||
| 04.02. | RFK Jr. clears key hurdle on path to become HHS secretary | ||
| 03.02. | Shares of psychedelics biotech nearly double on depression data | ||
| 03.02. | Pfizer drug acquired in $11B buyout confirms benefit in colon cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
